文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19大流行前两年体外膜氧合结局的演变:系统综述与荟萃分析

Evolving outcomes of extracorporeal membrane oxygenation during the first 2 years of the COVID-19 pandemic: a systematic review and meta-analysis.
PubMed 文献 · Crit Care · 2022-05-23
一句话结论COVID-19相关ARDS接受ECMO的患者合并死亡率为48.8%(95%CI 44.8-52.9%),且随大流行推进而升高,启动ECMO时应结合当时的情境死亡率估计。

该研究为系统综述与荟萃分析(CRD42021271202),检索MEDLINE、Embase、Cochrane和Scopus数据库2019年12月1日至2022年1月26日的研究,纳入52项研究共18,211例接受ECMO的COVID-19成人患者。合并死亡率为48.8%(95%CI 44.8-52.9%,高确定性);随入组时间推移死亡率升高:2020年上半年41.2%、2020年下半年46.4%、2021年上半年62.0%、2021年下半年46.5%(交互作用P=0.0014)。年龄、最后1例患者入组时间距2020年1月1日的时长、接受皮质类固醇的患者比例以及ECMO运行时间缩短是死亡率升高的预测因素。作者认为死亡原因可能为多因素,启动ECMO决策应包含启动时对死亡率的 contextual 估计。

要点

  • 接受ECMO的COVID-19成人患者合并死亡率为48.8%(95%CI 44.8-52.9%,高确定性)。
  • 死亡率随大流行阶段变化:2020年上半年41.2%、2020年下半年46.4%、2021年上半年62.0%、2021年下半年46.5%(交互作用P=0.0014)。
  • 死亡率升高的预测因素包括年龄、最后1例患者入组时间距2020年1月1日的时长、接受皮质类固醇的患者比例以及ECMO运行时间缩短。
  • 作者认为启动ECMO的决策应包含启动时对死亡率的 contextual 估计。

适用人群与场景

  • 接受ECMO的COVID-19成人患者。

研究设计与关键结果

  • 研究类型为系统综述与荟萃分析(CRD42021271202),检索MEDLINE、Embase、Cochrane和Scopus数据库2019年12月1日至2022年1月26日,纳入52项研究共18,211例接受ECMO的COVID-19成人患者。
  • 合并死亡率为48.8%(95%CI 44.8-52.9%,高确定性)。
  • 按入组时间分层死亡率:2020年上半年41.2%,2020年下半年46.4%,2021年上半年62.0%,2021年下半年46.5%,交互作用P=0.0014。
  • 死亡率升高的预测因素包括年龄、最后1例患者入组时间距2020年1月1日的时长、接受皮质类固醇的患者比例以及ECMO运行时间缩短。

证据类型、等级与局限

  • 证据类型为系统综述与荟萃分析,采用GRADE方法评估合并估计的确定性,合并死亡率为高确定性。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,随着这些患者结局的演变,启动ECMO的决策应包含启动时对死亡率的 contextual 估计。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) has been used extensively for coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). Reports early in the pandemic suggested that mortality in patients with COVID-19 receiving ECMO was comparable to non-COVID-19-related ARDS. However, subsequent reports suggested that mortality appeared to be increasing over time. Therefore, we conducted an updated systematic review and meta-analysis, to characterise changes in mortality over time and elucidate risk factors for poor outcomes.

METHODS: We conducted a meta-analysis (CRD42021271202), searching MEDLINE, Embase, Cochrane, and Scopus databases, from 1 December 2019 to 26 January 2022, for studies reporting on mortality among adults with COVID-19 receiving ECMO. We also captured hospital and intensive care unit lengths of stay, duration of mechanical ventilation and ECMO, as well as complications of ECMO. We conducted random-effects meta-analyses, assessed risk of bias of included studies using the Joanna Briggs Institute checklist and evaluated certainty of pooled estimates using GRADE methodology.

RESULTS: Of 4522 citations, we included 52 studies comprising 18,211 patients in the meta-analysis. The pooled mortality rate among patients with COVID-19 requiring ECMO was 48.8% (95% confidence interval 44.8-52.9%, high certainty). Mortality was higher among studies which enrolled patients later in the pandemic as opposed to earlier (1st half 2020: 41.2%, 2nd half 2020: 46.4%, 1st half 2021: 62.0%, 2nd half 2021: 46.5%, interaction p value = 0.0014). Predictors of increased mortality included age, the time of final patient enrolment from 1 January 2020, and the proportion of patients receiving corticosteroids, and reduced duration of ECMO run.

CONCLUSIONS: The mortality rate for patients receiving ECMO for COVID-19-related ARDS has increased as the pandemic has progressed. The reasons for this are likely multifactorial; however, as outcomes for these patients evolve, the decision to initiate ECMO should include the best contextual estimate of mortality at the time of ECMO initiation.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Ling RR, Ramanathan K, Sim JJL, et al. Evolving outcomes of extracorporeal membrane oxygenation during the first 2 years of the COVID-19 pandemic: a systematic review and meta-analysis. Crit Care. 2022. PMID: 35606884. doi:10.1186/s13054-022-04011-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。